Passive Targeted Drug Delivery of Venlafaxine HCl to the Brain by Modified Chitosan Nanoparticles: Characterization, Cellular Safety Assessment, and In Vivo Evaluation-Reference-Cited by-同舟云学术

Passive Targeted Drug Delivery of Venlafaxine HCl to the Brain by Modified Chitosan Nanoparticles: Characterization, Cellular Safety Assessment, and In Vivo Evaluation

Published:2023-05-11 Issue:3 Volume:18 Page:1441-1453
ISSN:1872-5120
Container-title:Journal of Pharmaceutical Innovation
language:en
Short-container-title:J Pharm Innov

Author:

Saeedi Majid,Morteza-Semnani Katayoun,Siahposht-Khachaki Ali,Akbari Jafar,Valizadeh Marjan,Sanaee Alireza,Jafarkhani Behrouz,Eghbali Mohammad,Zanjani Hasan Haji Hossein,Hashemi Seyyed Mohammad Hassan,Rahimnia Seyyed Mobin^ORCID

Funder

Mazandaran University of Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1007/s12247-023-09733-6.pdf

Reference56 articles.

1. Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.

2. Struzik L, et al. Treatments for generalized anxiety disorder. Expert Rev Neurother. 2004;4(2):285–94.

3. Zhou Y, et al. Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. Arch Pharmacal Res. 2015;38(7):1325–35.